Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738...

Our results open the possibility to use these epitopes as suitable anti-C. difficile vaccine antigens.

Clostridioides (C.) difficile is an important causative pathogen of nosocomial gastrointestinal infections in humans with an increasing incidence, morbidity, and mortality. The available treatment options against this pathogen are limited. The standard antibiotics are expensive, …

Researchers from Wake Forest School of Medicine in North Carolina have demonstrated that a common diabetes drug inhibits the spread of Clostridioides difficile, or C. diff -- a potentially life-threatening infection commonly acquired during hospital stays. The team will present their work virtually at the American Physiological Society's (APS) annual meeting at Experimental Biology 2021.

None of the 43 traditional antibiotics in the clinical pipeline that target WHO priority pathogens, Clostridioides difficile or tuberculosis sufficiently addresses drug resistance, according to a new report.WHO’s annual Antibacterial Pipeline Report reviews antibiotic candidates in early development or the clinical stages of testing to assess progress, identify gaps in drug resistance and

Microbial fermentation is currently still the major way to produce structural complicated clinical drugs. Yet, the low productivity and genetic instability of producing strains remain the bottlenecks in microbial pharmaceutical industry. Fidaxomicin is a microbial drug against the Clostridium diffic …

Clostridioides difficile infections (CDIs) are an urgent public health threat worldwide and are a leading cause of morbidity and mortality in healthcare settings. The increasing incidence and severity of infections combined with the scarcity of effective anti-CDI agents has made treatment of CDI ver …

With several potential treatments for serious infections currently in development, Destiny Pharma PLC has therefore found itself in an enviable position.

A wide range of synthetic polymers have been explored for antimicrobial activity. These materials usually contain both cationic and hydrophobic subunits because these two characteristics are prominent among host-defense peptides. Here, we describe a series of nylon-3 polymers containing only cationi …

Recruitment for a phase 2 trial of a novel antibiotic against Clostridium difficile (C diff) is proceeding after phase 1 demonstrated safety and tolerability.

Evogene's subsidiary Biomica released impressive pre-clinical data for its clinical candidate BMC128. Read this article to learn more about what this means for the company.

While antibiotic innovation—finding and designing new types of antibiotics and improving existing drugs—remains essential to combating antibiotic resistance, “outside-the-box” approaches to preventing and treating bacterial infections are also needed. Such nontraditional approaches encompass a variety of products.

/PRNewswire/ -- MGB Biopharma, a biopharmaceutical company developing MGB-BP-3, a novel antibacterial, for the treatment of Clostridioides difficile (CDI),...

MGB Biopharma's antibacterial treatment for Clostridium difficile infections cured 100% of the patients, who showed no recurrence four weeks after.

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that it will present new data from its SER-109 Phase 3 ECOSPOR III clinical study that confirm the intended pharmacological properties of this investigational microbiome therapeutic for recurrent C. difficile infection (CDI).

TAMPA, Fla., Jan. 11, 2021 (SEND2PRESS NEWSWIRE) –- While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 6, 2021--

XF-73 has been awarded both qualifying infectious disease product and Fast Track status by the US Food and Drug Administration

An investigational microbiome-based therapeutic for C difficile was found to exert continued efficacy 3 months after administration.